Abdominal Tumor
Prognostic value of American Joint Committee on Cancer-tumor regression grading combined with ypTN staging in patients with locally advanced rectal cancer
Jiawang Wei, Weiwei Xiao, Shaoyan Xi, Hui Chang, Qiaoxuan Wang, Liren Li, Huizhong Zhang, Zhifan Zeng, Peirong Ding, Yuanhong Gao
Published 2017-10-15
Cite as Chin J Radiat Oncol, 2017, 26(10): 1147-1150. DOI: 10.3760/cma.j.issn.1004-4221.2017.10.008
Abstract
ObjectiveTo investigate the prognostic value of American Joint Committee on Cancer-tumor regression grading (AJCC-TRG) combined with ypTN stage in patients with locally advanced rectal cancer (LARC), who were treated with neoadjuvant chemoradiotherapy, and to identify the subgroups with the worst prognosis.
MethodsA total of 263 patients with LARC, including 176 males and 87 females, with a median age of 55 years, were admitted to Sun Yat-sen University Cancer Center from 2004 to 2012.All the patients received neoadjuvant chemoradiotherapy before surgery and underwent total mesorectal excision at 6 to 8 weeks after radiotherapy. All the surgical specimens were reevaluated according to the AJCC (7th edition)-TRG system and ypTN staging criteria. The prognostic prediction by TRG combined with ypTN was evaluated using survival analysis. The Kaplan-Meier method was used to calculate the rates of overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The log-rank test was used for survival comparison and univariate prognostic analysis.
ResultsThe median follow-up was 60.1 months. The 5-year rates of OS, DFS, LRFS, and DMFS for all patients were 80.0%, 75.0%, 97.0%, and 81.0%, respectively. There were significant differences in OS, DFS, and DMFS between different ypT/TRG subgroups and different ypN/TRG subgroups (all P<0.05). ypT3-4/TRG 2-3 and ypN1-2/TRG 2-3 subgroups showed the worst prognosis. The 5-year rates of OS, DFS, and DMFS of the two subgroups were 66.9%/56.0%, 52.2%/41.4%, and 60.9%/46.0%, respectively.
ConclusionsA combination of AJCC-TRG system and ypTN staging can better predict the prognosis of LARC and identify the subgroups with the worst prognosis, which may provide a clinical guidance for postoperative individualized decision on adjuvant therapy for LARC.
Key words:
Rectal neoplasms/neoadjuvant therapy; Neoadjuvant therapy, radiotherapy; Neoadjuvant therapy, drug; Prognosis
Contributor Information
Jiawang Wei
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Weiwei Xiao
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Shaoyan Xi
Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Hui Chang
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Qiaoxuan Wang
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Liren Li
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Huizhong Zhang
Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Zhifan Zeng
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Peirong Ding
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Yuanhong Gao
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China